IP Library Granted Patent US 12,018,326
Granted Patent B2
US 12,018,326 · App. 17/511,391 · Granted Jun 25, 2024

Mutant pore

Inventors: Lakmal Jayasinghe (Oxford, GB); Elizabeth Jayne Wallace (Oxford, GB)
Assignee: Oxford Nanopore Technologies PLC
C12Q1/6869C07K14/245G01N33/48721C12Q2565/631
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,018,326
App. No.
17/511,391
Filed
Oct 26, 2021
Granted
Jun 25, 2024
Kind
B2
Art Unit
1652
USPC
435/202
Abstract

The invention relates to mutant forms of CsgG. The invention also relates to analyte detection and characterization using CsgG.

Claims (16)

1. An apparatus comprising a transmembrane protein pore inserted into an in vitro membrane, wherein the transmembrane protein pore comprises at least one CsgG monomer comprising a variant having 80% sequence identity to the amino acid sequence of SEQ ID NO: 2,wherein the variant comprises a substitution at position K94 selected from K94N, K94Q, K94R, K94F, K94Y, K94W, K94L, and K94S, and wherein the transmembrane pore facilitates translocation of an analyte through the transmembrane pore.

2. The apparatus of claim 1 , wherein the variant comprises K94Q or K94N.

3. The apparatus of claim 1 , wherein the variant further comprises; Q42K or Q42R; E44N or E44Q; L90R or L90K; N91R or N91K; I95R or I95K; A99R or A99K; E101H, E101K, E101N, E101Q or E101T; and/or Q114K.

4. The apparatus of claim 1 , wherein the variant further comprises

one or more of I41N, R93F/Y/W/L/I/V/N/Q/S, A98K/R, Q100K/R, G103F/W/S/N/K/R, T104R/K, A106R/K, I107R/K/W/F/Y/L/V, N108R/K, L113K/R, S115R/K, T117R/K, Y130W/F/H/Q/N, K135L/V/N/Q/S, E 170S/N/Q/K/R, S208V/I/F/W/Y/L/T, D233S/N/Q/K/R, D238S/N/Q/K/R and E244S/N/Q/K/R;

one or more mutations at the following positions R93, G103 and 1107 or one or more of R93F/Y/W/L/I/V/N/Q/S, G103F/W/S/N/K/R and I107R/K/W/F/Y/L/V;

one or more mutations at the following positions I41, T104, A106, N108, L113, S115, T117, E170, D233, D238 and E244 or one or more of I41N, T104R/K, A106R/K, N108R/K, L113K/R, S115R/K, T117R/K, E170S/N/Q/K/R, D233S/N/Q/K/R, D238S/N/Q/K/R and E244S/N/Q/K/R;

one or more mutations at the following positions (i) A98, (ii) Q100, (iii) G103 and (iv) 1107 or one or more of (i) A98R/K, (ii) Q100K/R, (iii) G103K/R and (iv) I107R/K;

one or more mutations at the following positions Y130, K135 and S208 or one or more of Y130W/F/H/Q/N, K135L/V/N/Q/S and R142Q/S;

one or more one or more of (i) Q87N/R/K, (ii) K94R/F/Y/W/L/S/N, (iii) R97F/Y/W/V/I/K/S/Q/H, (iv) N102K/Q/L/I/V/S/H and (v) R110F/G/N;

one or more of (i) D43S, (ii) E44S, (iii) N91K/R, (iv) Q114R/K and (v) D248S/N/Q/K/R;

one or more of Q87R/K, E101I/L/A/H and N102K;

F48S/N/Q/Y/W/I/V; or

F48H/R/K.

5. The apparatus of claim 1 , wherein the variant further comprises R192D/Q/F/S/T/N/E or R192D/Q/F/S/T.

6. The apparatus of claim 1 , wherein the variant further comprises: R97W; R93W; R93Y and R97Y; F191T; or deletion of V105, A106 and I107.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2022
From: JAYASINGHE, LAKMAL; WALLACE, ELIZABETH JAYNE
To: OXFORD NANOPORE TECHNOLOGIES LTD.
Reel/Frame 058657/0381 →
CHANGE OF NAME Recorded Jan 14, 2022
From: OXFORD NANOPORE TECHNOLOGIES LIMITED
To: OXFORD NANOPORE TECHNOLOGIES PLC
Reel/Frame 058737/0664 →
Priority Claims (3)
GB 1603656 · Mar 2, 2016 · national
GB 1603657 · Mar 2, 2016 · national
GB 1603658 · Mar 2, 2016 · national
Continuity (2)
Continuation 16081888
Related Publication 20220119879A1 · Apr 21, 2022
Cited By (7)
US 12,227,800 US 12,258,375 US 12,275,761 US 12,371,458 US 12,662,703 US 12,679,872 US 12,686,886